京都大学 · 医学
中島大輔教授の研究室では、脳死ドナーに限らず、感染を伴うドナー肺や無脳死臓器（DCD肺）の移植適合性を回復させるための新規救命技術を開発しています。特に体外肺灌流（EVLP）を用いた抗生物質投与や短時間の冷温灌流（HMP）による肺機能の回復が、移植後の予後を著しく改善する可能性を解明しています。また、生存供与ラバーリングトランスプラント（LDLLT）の臨床的有効性や長期的成績の検証も進め、希少な臓器資源の有効活用に貢献しています。
Figures are computed from collected data and may differ slightly.
Ex vivo lung perfusion (EVLP) is a platform to treat infected donor lungs with antibiotic therapy before lung transplantation. Human donor lungs that were rejected for transplantation because of clinical concern regarding infection were randomly assigned to two groups. In the antibiotic group (n = 8), lungs underwent EVLP for 12 h with high-dose antibiotics (ciprofloxacin 400 mg or azithromycin 500 mg, vancomycin 15 mg/kg, and meropenem 2 g). In the control group (n = 7), lungs underwent EVLP fo
Short-term HMP improved lung tissue energy levels that decreased during warm ischemia and ameliorated ischemia-reperfusion injury with decreased production of reactive oxygen species.
Living-donor lobar lung transplantation (LDLLT) has become an important life-saving option for patients with severe respiratory disorders, since it was developed by a group in the University of Southern California in 1993 and introduced in Japan in 1998 in order to address the current severe shortage of brain-dead donor organs. Although LDLLT candidates were basically limited to critically ill patients who would require hospitalization, the long-term use of steroids, and/or mechanical respirator
Short-term HMP could resuscitate ischemically damaged DCD lungs and ameliorate ischemia-reperfusion injury.
Open papers in the app to read, cite, and organize with AI.
